Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins.

@article{Ohi2003RecombinantET,
  title={Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins.},
  author={Hiroyuki Ohi and Mariko Tamano and Sukemasa Sudo and Noriko Okada},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2003},
  volume={41 1},
  pages={179-85}
}
BACKGROUND One of the complications of hemodialysis (HD) therapy is anemia caused by erythropoietin (EPO) deficiency. Recombinant EPO (rEPO) has been used routinely as a supplemental treatment. Erythrocyte expression of the complement regulatory proteins decay accelerating factor (DAF) and CD59 restricts complement activation and inhibits hemolysis. We hypothesized that the efficacy of rEPO treatment may be caused in part by the ability of rEPO to increase erythrocyte expression of DAF and CD59… CONTINUE READING